LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Strona główna・Stock List・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Closed

SectorHealthcare

4.26 -4.27

Buy Sell

Overview

Share price change

24h

Current

Min

4.25

Max

4.39

Key metrics
By Trading Economics
Income	9.6M -162M
Sales	-14M 5.2M
EPS	-0.36
Profit margin	-3,135.324
Employees	800
EBITDA	6.4M -141M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+74.55% upside

Market Stats
By TradingEconomics
Market Cap	-186M 2.2B
Previous open	8.53
Previous close	4.26

News Sentiment

By Acuity

50%

153 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

4.15 / 4.75 Support & Resistance

Recursion Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 gru 2025, 17:29 UTC

Acquisitions, Mergers, Takeovers

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

19 gru 2025, 16:47 UTC

Major Market Movers

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

19 gru 2025, 16:10 UTC

Acquisitions, Mergers, Takeovers

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

20 gru 2025, 19:00 UTC

Earnings

Consumer Confidence, Economic Activity Data, and a Short Trading Week for Christmas -- Barrons.com

19 gru 2025, 22:33 UTC

Earnings

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

19 gru 2025, 22:19 UTC

Earnings

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

19 gru 2025, 21:48 UTC

Acquisitions, Mergers, Takeovers

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 gru 2025, 21:44 UTC

Earnings

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19 gru 2025, 21:38 UTC

Earnings

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

19 gru 2025, 21:00 UTC

Market Talk

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

19 gru 2025, 20:23 UTC

Market Talk

Oil Futures End Down Week on Up Note -- Market Talk

19 gru 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

19 gru 2025, 18:38 UTC

Market Talk

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

19 gru 2025, 18:00 UTC

Market Talk

Earnings

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

19 gru 2025, 17:41 UTC

Earnings

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19 gru 2025, 17:24 UTC

Market Talk

Earnings

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

19 gru 2025, 17:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

19 gru 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

19 gru 2025, 16:29 UTC

Earnings

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

19 gru 2025, 16:20 UTC

Acquisitions, Mergers, Takeovers

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

19 gru 2025, 16:19 UTC

Acquisitions, Mergers, Takeovers

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

19 gru 2025, 16:18 UTC

Acquisitions, Mergers, Takeovers

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

19 gru 2025, 16:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19 gru 2025, 16:16 UTC

Market Talk

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

19 gru 2025, 16:05 UTC

Acquisitions, Mergers, Takeovers

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 gru 2025, 16:04 UTC

Acquisitions, Mergers, Takeovers

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 gru 2025, 15:37 UTC

Market Talk

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

19 gru 2025, 15:21 UTC

Market Talk

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

19 gru 2025, 15:09 UTC

Market Talk

Gold Flat But Set for Weekly Gains -- Market Talk

19 gru 2025, 15:09 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer Comparison

Price change

Recursion Pharmaceuticals Inc Forecast

Price Target

By TipRanks

74.55% upside

12 Months Forecast

Average 7.75 USD 74.55%

High 11 USD

Low 5 USD

Based on 6 Wall Street analysts offering 12 month price targets forRecursion Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Recursion Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

4.15 / 4.75Support & Resistance

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

153 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.